Emerging role of liquid biopsy in rat sarcoma virus mutated metastatic colorectal cancer: A case report

doi:10.4251/wjgo.v16.i1.234

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2330)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

WORD

HTML

1309

Figures (1-2)

190

Tables (1-4)

205

Sum=1779

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

139

Download

338

Sum=477

Jan 15, 2024 (publication date) through Dec 31, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastrointest Oncol. Jan 15, 2024; 16(1): 234-243
Published online Jan 15, 2024. doi: 10.4251/wjgo.v16.i1.234

Table 2 Treatment strategy

Case	1L	2L	3L	4L
Case 1	Oxaliplatin	Irinotecan	Irinotecan	NA³
	Folinic acid	Folinic acid	Folinic acid
	Fluorouracil	Fluorouracil	Fluorouracil
	Bevacizumab	Cetuximab	Bevacizumab
	(7 cycles)	(30 cycles)	(2 cycles)
Case 2	Oxaliplatin	Irinotecan	Irinotecan	Trifluridine/tipiracil
	Capecitabine	Folinic acid	Folinic acid
	Bevacizumab	Fluorouracil	Fluorouracil
	(4 cycles)	Bevacizumab	Cetuximab
		(4 cycles)	(5 cycles)
Case 3	Oxaliplatin	Irinotecan	Trifluridine/tipiracil (8 cycles)	Oxaliplatin
	Folinic acid	Folinic acid		Folinic acid
	Fluorouracil	Fluorouracil		Fluorouracil
	(8 cycles)	Bevacizumab (30 cycles)
Case 4	Oxaliplatin	Irinotecan	Trifluridine/tipiracil (3 cycles)	Fluorouracil
	Folinic acid	Folinic acid		Bevacizumab
	Fluorouracil	Fluorouracil
	(23 cycles)	Bevacizumab
		(12 cycles)
Case 5	Oxaliplatin	Irinotecan	Trifluridine/tipiracil (4 cycles)	Oxaliplatin
	Folinic acid	Folinic acid		Bevacizumab
	Fluorouracil	Fluorouracil
	(12 cycles)	Bevacizumab
		(11 cycles)
Case 6	Oxaliplatin	Irinotecan	Trifluridine/tipiracil (2 cycles)	NA
	Folinic acid	Folinic acid
	Fluorouracil	Fluorouracil
	Bevacizumab	Bevacizumab
	(7 cycles)	(21 cycles)
Case 7	Oxaliplatin	Irinotecan	Trifluridine/tipiracil (5 cycles)	Oxaliplatin
	Folinic acid	Folinic acid		Capecitabine
	Fluorouracil	Fluorouracil		Bevacizumab
	Bevacizumab	Cetuximab
	(9 cycles)	(16 cycles)
Case 8	Oxaliplatin	Oxaliplatin	NA¹	NA
	Folinic acid	Capecitabine
	Fluorouracil	Bevacizumab
	Bevacizumab	(5 cycles)
	(12 cycles)
Case 9	Oxaliplatin	Irinotecan	Trifluridine/tipiracil (4 cycles)	Oxaliplatin
	Capecitabine	Folinic acid		Capecitabine
	Bevacizumab	Fluorouracil		Bevacizumab
	(6 cycles)	Bevacizumab
		(22 cycles)
Case 10	Oxaliplatin	Irinotecan	Trifluridine/tipiracil (12 cycles)	NA
	Folinic acid	Folinic acid
	Fluorouracil	Fluorouracil
	Bevacizumab	Bevacizumab
	(10 cycles)	(7 cycles)
Case 11	Oxaliplatin	Irinotecan	NA²	NA
	Capecitabine	Folinic acid
	Bevacizumab	Fluorouracil
	(25 cycles)	Cetuximab
		(8 cycles)

¹The patient had no conditions to change treatment.

²Stable disease.

³Death. 1L: First line; 2L: Second line; 3L: Third line; 4L: Fourth line; NA: Not applied.

Citation: Gramaça J, Fernandes IG, Trabulo C, Gonçalves J, dos Santos RG, Baptista A, Pina I. Emerging role of liquid biopsy in rat sarcoma virus mutated metastatic colorectal cancer: A case report. World J Gastrointest Oncol 2024; 16(1): 234-243
URL: https://www.wjgnet.com/1948-5204/full/v16/i1/234.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i1.234